Tandem Diabetes Care expands connected-care ecosystem by adding Android platform
Tandem Diabetes Care, Inc., a global leader in insulin delivery and diabetes technology, has announced that its Tandem Mobi automated insulin delivery system is now compatible with Android smartphones in the United States through the Tandem Mobi mobile app. The expansion significantly broadens access to advanced diabetes technology, enabling more patients to manage their condition directly through their personal mobile devices.
The Tandem Mobi system, recognized as the world’s smallest durable automated insulin delivery device, was initially launched with compatible iPhone models in 2024. With the latest update, users with Android smartphones can now access the same mobile-enabled diabetes management experience, offering greater flexibility and accessibility for individuals living with diabetes.
John Sheridan, President and Chief Executive Officer of Tandem Diabetes Care, highlighted the importance of expanding device compatibility. He noted that bringing Tandem Mobi to Android users represents a major step toward providing more choice in diabetes management technology. By extending the platform to additional mobile ecosystems, the company aims to help more people benefit from the convenience and control offered by the Tandem Mobi system.
At the core of the device is the Control-IQ+ technology predictive algorithm, an advanced automated insulin delivery system designed to optimize blood glucose management. Clinical data have demonstrated notable benefits, including improved glucose control from the first day of use, approximately 79 percent time in range during daily use, and up to 90 percent overnight time in range for many patients. These outcomes highlight the growing role of intelligent medical technology in improving diabetes care and patient outcomes.
Health Technology Insights: https://healthtechnologyinsights.com/how-global-health-systems-are-adapting-wound-care-for-aging-and-diabetic-populations/
Tandem Mobi combines these clinical benefits with enhanced portability and wearable flexibility. The compact pump can be worn directly on the body using an adhesive sleeve, clipped discreetly to clothing, or placed in a small pocket, giving patients greater freedom in how they manage their insulin therapy throughout the day.
The Tandem Mobi mobile app serves as the central control interface for the system. Designed with a secure and intuitive user experience, the application allows patients to monitor and manage their insulin delivery directly from their smartphones. The platform also connects to the Tandem Source data system, enabling healthcare providers to review treatment data, monitor patient progress, and support more informed clinical decisions.
The Android version of the Tandem Mobi mobile app received clearance from the U.S. Food and Drug Administration in November 2025, followed by a limited release in December 2025. With the broader availability now underway, Tandem Diabetes Care continues to strengthen its commitment to advancing diabetes technology and improving the daily lives of people living with the condition.
Health Technology Insights: https://healthtechnologyinsights.com/how-mobile-first-patient-support-will-define-the-next-generation-of-telehealth/
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
